Wednesday, December 9, 2015
Pfizer has announced the first-ever recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards.
Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has accelerated its study startup timelines globally and has achieved a reduction of mean startup cycle times by up to 25%.
Parkinson’s patients have some good news: Charles River Laboratories today announced a significant expansion of its work with small molecule LRRK2 inhibitors, funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). [Read More]
Amgen and Merck, known as MSD outside the U.S. and Canada, today announced a cancer immunotherapy collaboration to support a phase Ib/III study investigating BLINCYTO (blinatumomab) in combination with KEYTRUDA (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin’s lymphoma.
Insys Therapeutics has issued the following response to a recent report containing accusations centered on adverse events and diversion related to the company’s breakthrough cancer pain drug, Subsys:
Algorithme Pharma USA, an Altasciences company, has selected Verified Clinical Trials (VCT), the global clinical trial research subject database registry, to counter attempts at duplicate enrollment in clinical trial research.